DK0885887T3 - Sulfonamidinhibitorer af HIV-aspartylprotease - Google Patents
Sulfonamidinhibitorer af HIV-aspartylproteaseInfo
- Publication number
- DK0885887T3 DK0885887T3 DK98113921T DK98113921T DK0885887T3 DK 0885887 T3 DK0885887 T3 DK 0885887T3 DK 98113921 T DK98113921 T DK 98113921T DK 98113921 T DK98113921 T DK 98113921T DK 0885887 T3 DK0885887 T3 DK 0885887T3
- Authority
- DK
- Denmark
- Prior art keywords
- aspartyl protease
- hiv aspartyl
- sulfonamide inhibitors
- sulfonamide
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids
- C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94198292A | 1992-09-08 | 1992-09-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0885887T3 true DK0885887T3 (da) | 2003-09-22 |
Family
ID=25477403
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK98113921T DK0885887T3 (da) | 1992-09-08 | 1993-09-07 | Sulfonamidinhibitorer af HIV-aspartylprotease |
DK93921428T DK0659181T3 (da) | 1992-09-08 | 1993-09-07 | Sulfonamidinhibitorer af HIV-aspartylprotease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93921428T DK0659181T3 (da) | 1992-09-08 | 1993-09-07 | Sulfonamidinhibitorer af HIV-aspartylprotease |
Country Status (41)
Country | Link |
---|---|
US (7) | US5585397A (da) |
EP (2) | EP0885887B1 (da) |
JP (1) | JP3012002B2 (da) |
KR (1) | KR100262056B1 (da) |
CN (1) | CN1061339C (da) |
AP (1) | AP390A (da) |
AT (2) | ATE178598T1 (da) |
AU (1) | AU691160B2 (da) |
BG (1) | BG62488B1 (da) |
BR (1) | BR1100824A (da) |
CA (1) | CA2143208C (da) |
CO (1) | CO4870779A1 (da) |
CY (1) | CY2164B1 (da) |
CZ (1) | CZ289475B6 (da) |
DE (3) | DE69333012T2 (da) |
DK (2) | DK0885887T3 (da) |
ES (2) | ES2200243T3 (da) |
FI (1) | FI120685B (da) |
GE (1) | GEP20012579B (da) |
GR (1) | GR3030719T3 (da) |
HK (2) | HK1023561A1 (da) |
HU (1) | HU228198B1 (da) |
IL (1) | IL106927A (da) |
IS (1) | IS2334B (da) |
LT (1) | LT3302B (da) |
LU (1) | LU90736I2 (da) |
MX (1) | MXPA03010538A (da) |
MY (1) | MY142901A (da) |
NL (1) | NL300039I2 (da) |
NO (2) | NO303444B1 (da) |
NZ (2) | NZ256238A (da) |
PH (1) | PH31251A (da) |
PL (1) | PL185635B1 (da) |
PT (1) | PT885887E (da) |
RO (1) | RO118747B1 (da) |
RU (1) | RU2135496C1 (da) |
SG (1) | SG43862A1 (da) |
SK (1) | SK281360B6 (da) |
TW (1) | TW254927B (da) |
UA (1) | UA44694C2 (da) |
WO (1) | WO1994005639A1 (da) |
Families Citing this family (298)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6878728B1 (en) | 1999-06-11 | 2005-04-12 | Vertex Pharmaceutical Incorporated | Inhibitors of aspartyl protease |
US20040122000A1 (en) | 1981-01-07 | 2004-06-24 | Vertex Pharmaceuticals Incorporated. | Inhibitors of aspartyl protease |
US5962490A (en) * | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5736509A (en) * | 1990-12-14 | 1998-04-07 | Texas Biotechnology Corporation | Cyclic peptide surface feature mimics of endothelin |
WO1993020525A1 (en) * | 1992-03-27 | 1993-10-14 | Akiko Itai | Method of searching the structure of stable biopolymer-ligand molecule composite |
US6046190A (en) * | 1992-08-25 | 2000-04-04 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
US5843946A (en) | 1992-08-25 | 1998-12-01 | G.D. Searle & Co. | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US7141609B2 (en) | 1992-08-25 | 2006-11-28 | G.D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US5968942A (en) * | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US6743929B1 (en) * | 1992-08-25 | 2004-06-01 | G. D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US5783701A (en) * | 1992-09-08 | 1998-07-21 | Vertex Pharmaceuticals, Incorporated | Sulfonamide inhibitors of aspartyl protease |
IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
CA2142997A1 (en) | 1992-10-30 | 1994-05-11 | Michael L. Vazquez | Hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors |
EP0885881B1 (en) * | 1992-10-30 | 2003-03-12 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors |
US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5846993A (en) * | 1992-12-22 | 1998-12-08 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US6342610B2 (en) | 1993-05-20 | 2002-01-29 | Texas Biotechnology Corp. | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US6030991A (en) * | 1993-05-20 | 2000-02-29 | Texas Biotechnology Corp. | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US5846981A (en) * | 1993-05-28 | 1998-12-08 | Gpi Nil Holdings Inc. | Inhibitors of rotamase enzyme activity |
US5798355A (en) * | 1995-06-07 | 1998-08-25 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity |
US7831470B1 (en) * | 1996-09-04 | 2010-11-09 | Walker Digital, Llc | Method and apparatus for facilitating electronic commerce through providing cross-benefits during a transaction |
US5750648A (en) * | 1993-08-20 | 1998-05-12 | G.D. Searle & Co. | Retroviral protease inhibitors and combinations thereof |
IL110752A (en) * | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5559158A (en) * | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
US5602119A (en) * | 1993-10-29 | 1997-02-11 | Vazquez; Michael L. | Succinoylamino hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors |
US5527829A (en) * | 1994-05-23 | 1996-06-18 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
UA49803C2 (uk) * | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Спосіб лікування ретровірусних інфекцій |
US20030207813A1 (en) * | 1996-12-09 | 2003-11-06 | G.D. Searle | Retroviral protease inhibitor combinations |
US5831117A (en) | 1995-01-20 | 1998-11-03 | G. D. Searle & Co. | Method of preparing retroviral protease inhibitor intermediates |
WO1996022287A1 (en) | 1995-01-20 | 1996-07-25 | G.D. Searle & Co. | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors |
US5756533A (en) * | 1995-03-10 | 1998-05-26 | G.D. Searle & Co. | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US6140505A (en) * | 1995-03-10 | 2000-10-31 | G. D. Searle & Co. | Synthesis of benzo fused heterocyclic sulfonyl chlorides |
US6150556A (en) * | 1995-03-10 | 2000-11-21 | G. D. Dearle & Co. | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US6407134B1 (en) | 1995-03-10 | 2002-06-18 | G. D. Searle & Co. | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
EP1188766A1 (en) | 1995-03-10 | 2002-03-20 | G.D. Searle & Co. | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5776971A (en) * | 1995-03-10 | 1998-07-07 | G.D. Searle & Co. | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
JP4124818B2 (ja) * | 1995-03-10 | 2008-07-23 | ジー.ディー.サール アンド カンパニー | ヘテロシクロカルボニルアミノ酸ヒドロキシエチルアミノスルホンアミドレトロウイルスプロテアーゼインヒビター |
US6143788A (en) * | 1995-03-10 | 2000-11-07 | G.D. Searle & Co. | Bis-amino acid hydroxyethlamino sulfonamide retroviral protease inhibitors |
US7339078B2 (en) * | 1995-03-10 | 2008-03-04 | G.D. Searle Llc | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US6861539B1 (en) | 1995-03-10 | 2005-03-01 | G. D. Searle & Co. | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5691372A (en) * | 1995-04-19 | 1997-11-25 | Vertex Pharmaceuticals Incorporated | Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease |
US5859031A (en) * | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
US5696135A (en) * | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US5942253A (en) | 1995-10-12 | 1999-08-24 | Immunex Corporation | Prolonged release of GM-CSF |
US5801197A (en) * | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
EP1097919A3 (en) | 1995-11-17 | 2003-08-06 | Ajinomoto Co., Inc. | Process for producing 4-amino-3-oxo-butanoic acid ester |
US5646180A (en) * | 1995-12-05 | 1997-07-08 | Vertex Pharmaceuticals Incorporated | Treatment of the CNS effects of HIV |
US5914332A (en) | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5977117A (en) * | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
GEP20012464B (en) * | 1996-03-22 | 2001-06-25 | Glaxo Group Ltd | Compositions Comprising an HIV Protease Inhibitor Such As VX 478 and a Water Soluble Vitamin E Compound Such As Vitamin E-TPGS |
MY126358A (en) * | 1996-03-22 | 2006-09-29 | Glaxo Group Ltd | Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs |
US6730679B1 (en) | 1996-03-22 | 2004-05-04 | Smithkline Beecham Corporation | Pharmaceutical formulations |
US5958905A (en) * | 1996-03-26 | 1999-09-28 | Texas Biotechnology Corporation | Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin |
US5804585A (en) | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
AP9801419A0 (en) * | 1996-06-25 | 1998-12-31 | Glaxo Group Ltd | Combination comprising VX478, zidovudine, FTC and or 3 |
US6486136B1 (en) * | 1996-06-25 | 2002-11-26 | Smithkline Beecham Corporation | Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV |
US5962725A (en) | 1996-09-05 | 1999-10-05 | Agouron Pharmaceuticals, Inc. | Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir |
US5705647A (en) * | 1996-09-05 | 1998-01-06 | Agouron Pharmaceuticals, Inc. | Intermediates for making HIV-protease inhibitors |
US5925759A (en) | 1996-09-05 | 1999-07-20 | Agouron Pharmaceuticals, Inc. | Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors |
US6218424B1 (en) | 1996-09-25 | 2001-04-17 | Gpi Nil Holdings, Inc. | Heterocyclic ketone and thioester compounds and uses |
US5801187A (en) * | 1996-09-25 | 1998-09-01 | Gpi-Nil Holdings, Inc. | Heterocyclic esters and amides |
US5786378A (en) * | 1996-09-25 | 1998-07-28 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters |
IN183408B (da) * | 1996-11-20 | 1999-12-25 | Kuraray Co | |
ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
US6232333B1 (en) | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
US5874449A (en) * | 1996-12-31 | 1999-02-23 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of heterocyclic thioesters |
US5935989A (en) | 1996-12-31 | 1999-08-10 | Gpi Nil Holdings Inc. | N-linked ureas and carbamates of heterocyclic thioesters |
JP2002515051A (ja) | 1996-12-31 | 2002-05-21 | ジーピーアイ エヌアイエル ホールディングス インコーポレイテッド | ヘテロ環式チオエステルのn−結合スルホンアミド |
EP0959882A4 (en) | 1996-12-31 | 2001-12-05 | N-LINKED UREAS AND CARBAMATES OF HETEROCYCLIC THIOESTERS | |
US5721256A (en) | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
US5846979A (en) | 1997-02-28 | 1998-12-08 | Gpi Nil Holdings, Inc. | N-oxides of heterocyclic esters, amides, thioesters, and ketones |
US6001851A (en) * | 1997-03-13 | 1999-12-14 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
BR9812258A (pt) | 1997-04-28 | 2000-07-25 | Texas Biotechnology Corp | Sulfonamidas para tratamento de distúrbios mediados por endotelina |
US5783705A (en) * | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
CN1255119A (zh) * | 1997-05-08 | 2000-05-31 | 史密丝克莱恩比彻姆公司 | 蛋白酶抑制剂 |
US6274602B1 (en) | 1998-06-03 | 2001-08-14 | Gpi Nil Holdings, Inc. | Heterocyclic thioester and ketone hair growth compositions and uses |
US6271244B1 (en) | 1998-06-03 | 2001-08-07 | Gpi Nil Holdings, Inc. | N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses |
US6187784B1 (en) | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Pipecolic acid derivative hair growth compositions and uses |
US5945441A (en) | 1997-06-04 | 1999-08-31 | Gpi Nil Holdings, Inc. | Pyrrolidine carboxylate hair revitalizing agents |
US6187796B1 (en) | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Sulfone hair growth compositions and uses |
GB9712253D0 (en) * | 1997-06-13 | 1997-08-13 | Glaxo Group Ltd | Antiviral compound |
US6348474B1 (en) | 1997-06-27 | 2002-02-19 | Fujisawa Pharmaceutical Co., Ltd. | Sulfonamide compounds and medicinal use thereof |
US6084107A (en) * | 1997-09-05 | 2000-07-04 | Agouron Pharmaceuticals, Inc. | Intermediates for making HIV-protease inhibitors |
US6576231B2 (en) * | 1997-09-12 | 2003-06-10 | Schering Ag | Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor |
US6180634B1 (en) * | 1997-11-13 | 2001-01-30 | Merck & Co., Inc. | Combination therapy for the treatment of AIDS |
AU2012199A (en) * | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs of aspartyl protease inhibitors |
US6436989B1 (en) * | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
AU2010299A (en) * | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs os aspartyl protease inhibitors |
TR200002402T2 (tr) * | 1997-12-24 | 2001-01-22 | Vertex Pharmaceuticals Incorporated | Aspartil proteaz inhibitörü ön-ilaçlar. |
GB9805898D0 (en) * | 1998-03-20 | 1998-05-13 | Glaxo Group Ltd | Process for the sythesis of hiv protease inhibitors |
US6251906B1 (en) | 1998-05-15 | 2001-06-26 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US6331537B1 (en) | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
WO1999062487A1 (en) | 1998-06-03 | 1999-12-09 | Gpi Nil Holdings, Inc. | Heterocyclic ester and amide hair growth compositions and uses |
US6172087B1 (en) | 1998-06-03 | 2001-01-09 | Gpi Nil Holding, Inc. | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
WO1999062880A1 (en) | 1998-06-03 | 1999-12-09 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres |
AP1717A (en) | 1998-06-19 | 2007-01-30 | Vertex Pharma | Sulfonamide inhibitors of aspartyl protease. |
DE69943266D1 (de) | 1998-06-23 | 2011-04-21 | Trustees For The University Of Illinois Board Of | Arzneimittel zur behandlung von hiv-infizierten säugetieren |
US6538006B1 (en) | 1998-07-08 | 2003-03-25 | Pharmacia Corporation | Retroviral protease inhibitors |
US6713290B2 (en) | 1998-07-24 | 2004-03-30 | Samsung Fine Chemicals Co., Ltd. | Process for preparing optically pure (S)-3-hydroxy-γ-butyrolactone |
JP3614366B2 (ja) | 1998-07-24 | 2005-01-26 | サムスン ファイン ケミカルズ カンパニー リミテッド | 光学的に純粋な(s)−3,4−ジヒドロキシ酪酸誘導体の製造方法 |
US6376517B1 (en) | 1998-08-14 | 2002-04-23 | Gpi Nil Holdings, Inc. | Pipecolic acid derivatives for vision and memory disorders |
US6395758B1 (en) | 1998-08-14 | 2002-05-28 | Gpi Nil Holdings, Inc. | Small molecule carbamates or ureas for vision and memory disorders |
US6333340B1 (en) | 1998-08-14 | 2001-12-25 | Gpi Nil Holdings, Inc. | Small molecule sulfonamides for vision and memory disorders |
US7338976B1 (en) | 1998-08-14 | 2008-03-04 | Gpi Nil Holdings, Inc. | Heterocyclic esters or amides for vision and memory disorders |
US6506788B1 (en) | 1998-08-14 | 2003-01-14 | Gpi Nil Holdings, Inc. | N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders |
US6218423B1 (en) | 1998-08-14 | 2001-04-17 | Gpi Nil Holdings, Inc. | Pyrrolidine derivatives for vision and memory disorders |
US6399648B1 (en) | 1998-08-14 | 2002-06-04 | Gpi Nil Holdings, Inc. | N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders |
US6339101B1 (en) | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
US6384056B1 (en) | 1998-08-14 | 2002-05-07 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters or ketones for vision and memory disorders |
US6335348B1 (en) | 1998-08-14 | 2002-01-01 | Gpi Nil Holdings, Inc. | Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders |
US6337340B1 (en) | 1998-08-14 | 2002-01-08 | Gpi Nil Holdings, Inc. | Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders |
US6462072B1 (en) | 1998-09-21 | 2002-10-08 | Gpi Nil Holdings, Inc. | Cyclic ester or amide derivatives |
US7115584B2 (en) * | 1999-01-22 | 2006-10-03 | Emory University | HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine |
US7635690B2 (en) * | 1999-01-22 | 2009-12-22 | Emory University | HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine |
JP4814427B2 (ja) * | 1999-02-12 | 2011-11-16 | バーテックス ファーマシューティカルズ インコーポレイテッド | アスパルチルプロテアーゼのインヒビター |
TWI260322B (en) | 1999-02-12 | 2006-08-21 | Vertex Pharma | Inhibitors of aspartyl protease |
AR031520A1 (es) * | 1999-06-11 | 2003-09-24 | Vertex Pharma | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion |
GB9914821D0 (en) * | 1999-06-24 | 1999-08-25 | Glaxo Group Ltd | Compounds |
PL204924B1 (pl) * | 1999-10-06 | 2010-02-26 | Tibotec Pharm Ltd | Heksahydrofuro [2,3-b] furanylo-3-N-{3(1,3-benzodioksolilo-5-sulfonylo) (izobutylo) amino] -1-benzylo-2-hydroksypropylo} karbaminian oraz jego zastosowanie |
US6548706B2 (en) * | 1999-12-23 | 2003-04-15 | Aerojet Fine Chemicals Llc | Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines |
ATE401298T1 (de) | 1999-12-23 | 2008-08-15 | Ampac Fine Chemicals Llc | Verbessertes verfahren zur herstellung von 2s,3s- n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)- - nitrobenzenesulfonylamid hydrochlorid und anderen derivaten von 2-hydroxy-1,3-diamin |
US6391919B1 (en) | 2000-01-12 | 2002-05-21 | Bristol-Myers Squibb Pharma Company | Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors |
ES2387579T3 (es) | 2000-01-19 | 2012-09-26 | Abbott Laboratories | Formulaciones farmacéuticas de inhibidores de proteasa de VIH mejoradas |
PE20020276A1 (es) * | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
US6617310B2 (en) | 2000-07-19 | 2003-09-09 | Bristol-Myers Squibb Pharma Company | Phosphate esters of bis-amino acid sulfonamides containing substituted benzyl amines |
PL213327B1 (pl) * | 2001-02-14 | 2013-02-28 | Tibotec Pharm Ltd | Zwiazki 2-(podstawione-amino)-benzotiazolosulfonamidowe, sposób ich wytwarzania oraz ich zastosowanie |
US6756063B2 (en) | 2001-03-29 | 2004-06-29 | Zoltan Laboratories, Llc | Methods and compositions for the treatment of human and animal cancers |
AP1544A (en) * | 2001-04-09 | 2006-01-12 | Tibotec Pharm Ltd | Broadspectrum 2- (substituted-amino) -benzoxazole sulfonamide HIV protease inhibitors. |
US6696494B2 (en) | 2001-10-22 | 2004-02-24 | Enanta Pharmaceuticals, Inc. | α-hydroxyarylbutanamine inhibitors of aspartyl protease |
WO2003057173A2 (en) * | 2002-01-07 | 2003-07-17 | Sequoia Pharmaceuticals | Broad spectrum inhibitors |
EP2266590A3 (en) | 2002-02-22 | 2011-04-20 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
US7157489B2 (en) * | 2002-03-12 | 2007-01-02 | The Board Of Trustees Of The University Of Illinois | HIV protease inhibitors |
EA008775B1 (ru) | 2002-04-26 | 2007-08-31 | Джилид Сайэнс, Инк. | Ингибиторы протеазы вич для лечения инфекции вич и фармацевтическая композиция |
BR0310089A (pt) | 2002-05-17 | 2005-02-15 | Tibotec Pharm Ltd | Inibidores de protease de hiv de sulfonamida benzisoxazol substituìda de largo espectro |
AU2003276047A1 (en) * | 2002-06-17 | 2003-12-31 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
US7115652B2 (en) * | 2002-06-17 | 2006-10-03 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
PL375307A1 (en) * | 2002-08-14 | 2005-11-28 | Tibotec Pharmaceuticals Ltd. | Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors |
UY27967A1 (es) * | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
SI1546088T1 (sl) * | 2002-10-03 | 2015-04-30 | Novaremed Ltd. | Spojine za uporabo v zdravljenju avtoimunskih bolezni, imunoalergijskih bolezni in zavrnitve transpalantata organa ali tkiva |
US6713639B1 (en) | 2002-10-28 | 2004-03-30 | Council Of Scientific And Industrial Research | Process for preparing enantiomerically pure (S)-3-hydroxy-gamma-butyrolactone |
EP1562897B1 (en) * | 2002-11-12 | 2009-09-16 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease |
BR0316629A (pt) * | 2002-11-27 | 2005-10-11 | Elan Pharm Inc | Uréias e carbamatos substituìdos |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
US7470724B2 (en) * | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
JP2006524710A (ja) * | 2003-04-25 | 2006-11-02 | ギリアード サイエンシーズ, インコーポレイテッド | キナーゼインヒビターホスホネート抱合体 |
US7300924B2 (en) * | 2003-04-25 | 2007-11-27 | Gilead Sciences, Inc. | Anti-infective phosphonate analogs |
US7407965B2 (en) * | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
CN101410120A (zh) * | 2003-04-25 | 2009-04-15 | 吉里德科学公司 | 抗炎的膦酸酯化合物 |
WO2005002626A2 (en) * | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
DK1628685T3 (da) * | 2003-04-25 | 2011-03-21 | Gilead Sciences Inc | Antivirale phosphonatanaloge |
US20090247488A1 (en) * | 2003-04-25 | 2009-10-01 | Carina Cannizzaro | Anti-inflammatory phosphonate compounds |
US20050261237A1 (en) * | 2003-04-25 | 2005-11-24 | Boojamra Constantine G | Nucleoside phosphonate analogs |
US7432261B2 (en) * | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
WO2004096287A2 (en) * | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
CN100432038C (zh) * | 2003-09-19 | 2008-11-12 | 宇部兴产株式会社 | 腈化合物、羧酸化合物或羧酸酯化合物的制备方法 |
WO2005028410A1 (ja) * | 2003-09-19 | 2005-03-31 | Ube Industries, Ltd. | ニトリル化合物、カルボン酸化合物又はカルボン酸エステル化合物の製法 |
WO2005044279A1 (en) * | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
WO2005044308A1 (en) * | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
US20050131042A1 (en) * | 2003-12-11 | 2005-06-16 | Flentge Charles A. | HIV protease inhibiting compounds |
US8193227B2 (en) | 2003-12-11 | 2012-06-05 | Abbott Laboratories | HIV protease inhibiting compounds |
US20070281907A1 (en) * | 2003-12-22 | 2007-12-06 | Watkins William J | Kinase Inhibitor Phosphonate Conjugates |
MXPA06006899A (es) * | 2003-12-22 | 2006-09-04 | Gilead Sciences Inc | Derivados de carbovir y abacavir 4'-sustituidos asi como compuestos relacionados con actividad antiviral de virus de inmunodeficiencia humana y virus de la hepatitis c. |
US20050153990A1 (en) * | 2003-12-22 | 2005-07-14 | Watkins William J. | Phosphonate substituted kinase inhibitors |
ME01059B (me) | 2003-12-23 | 2012-10-20 | Janssen Sciences Ireland Uc | Proces za pripremanje (3r,3as,6ar)-heksahidrofuro [2,3-b] furan-3-il (1s,2r)-3-[[(4-aminofenil) sulfonil] (izobutil) amino]-1-benzil-2- hidroksipropilkarbamata |
US7200207B2 (en) * | 2004-03-13 | 2007-04-03 | Intrado Inc. | Communication network for providing emergency services |
US7674829B2 (en) * | 2004-03-26 | 2010-03-09 | Novaremed Limited | Compounds for the treatment of AIDS and other viral diseases |
US7871991B2 (en) | 2004-07-27 | 2011-01-18 | Gilead Sciences, Inc. | Phosphonate analogs of HIV inhibitor compounds |
US20060135510A1 (en) * | 2004-10-13 | 2006-06-22 | The Trustees Of The University Of Pennsylvania | Use of amprenavir as a radiation sensitizer |
US20060116397A1 (en) * | 2004-10-13 | 2006-06-01 | The Trustees Of The University Of Pennsylvania | Use of saquinavir as a radiation sensitizer |
WO2006058905A1 (en) | 2004-12-01 | 2006-06-08 | Devgen Nv | 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY |
EP1969939A3 (en) * | 2004-12-17 | 2008-12-03 | Devgen NV | Nematicidal compositions |
WO2006104646A1 (en) * | 2005-03-11 | 2006-10-05 | Smithkline Beecham Corporation | Hiv protease inhibitors |
US20080009517A1 (en) * | 2005-10-13 | 2008-01-10 | The Trustees Of The University Of Pennsylvania | Use of nelfinavir as a radiation sensitizer |
DK2026775T3 (da) * | 2006-05-09 | 2015-06-29 | Novaremed Ltd | Anvendelse af syk-tyrosinkinase-inhibitorer til behandling af celleproliferative lidelser |
EP2131865B1 (en) | 2007-03-12 | 2014-12-17 | Nektar Therapeutics | Oligomer-protease inhibitor conjugates |
RU2009143867A (ru) | 2007-04-27 | 2011-06-10 | Тиботек Фармасьютикалз Лтд. (Ie) | Способы получения производных n-изобутил-n-(2-гидрокси-3-амино-4-фенилбутил)-пара-нитробензолсульфониламида |
US20090075942A1 (en) * | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched fosamprenavir |
GB2452952A (en) * | 2007-09-20 | 2009-03-25 | Npil Pharmaceuticals | N-[2-Hydroxy-3-(hydroxycarbonylamino)-3-methyl]-N-methyl-sulphonamide derivatives via N-[2-oxo-3-(hydroxycarbonylamino)-3-methyl]-N-methyl-imine skeleton |
WO2009042093A1 (en) * | 2007-09-25 | 2009-04-02 | Merck & Co., Inc. | Hiv protease inhibitors |
GB0804213D0 (en) * | 2008-03-06 | 2008-04-16 | New Era Biotech Ltd | A method of printing or preventing pain |
US9095620B2 (en) * | 2008-03-12 | 2015-08-04 | Nektar Therapeutics | Reagents |
EP2116236A1 (en) | 2008-04-21 | 2009-11-11 | Université de Mons-Hainaut | Bisbenzamidine derivatives for use as antioxidant |
CN102056897B (zh) * | 2008-06-05 | 2014-05-07 | 旭化成制药株式会社 | 磺酰胺化合物及其用途 |
US8791135B2 (en) * | 2008-07-01 | 2014-07-29 | Purdue Research Foundation | Nonpeptide HIV-1 protease inhibitors |
MX2011000306A (es) * | 2008-07-08 | 2011-03-15 | Gilead Sciences Inc | Sales de compuestos inhibidores de hiv. |
CA2762582A1 (en) | 2009-05-27 | 2010-12-02 | Merck Sharp & Dohme Corp. | Hiv protease inhibitors |
EP2440249A2 (en) | 2009-06-12 | 2012-04-18 | Nektar Therapeutics | Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety |
US8802734B2 (en) * | 2009-09-09 | 2014-08-12 | Novaremed Limited | Method of treating or preventing pain |
WO2011061590A1 (en) | 2009-11-17 | 2011-05-26 | Hetero Research Foundation | Novel carboxamide derivatives as hiv inhibitors |
DE102010004957A1 (de) | 2010-01-14 | 2011-07-21 | Universitätsklinikum Jena, 07743 | Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung |
US20120328568A1 (en) | 2010-02-12 | 2012-12-27 | Emory University | Compositions and uses of lectins |
KR101794009B1 (ko) | 2010-03-02 | 2017-11-07 | 주식회사 피에이치파마 | Rock 저해제로서 헤테로고리 아미드 |
CN102190638A (zh) * | 2010-03-16 | 2011-09-21 | 中国科学院上海药物研究所 | 联芳基醇二胺类化合物、其药物组合物、制备方法及应用 |
EP2579892A2 (en) | 2010-06-09 | 2013-04-17 | Vaccine Technologies, Incorporated | Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment |
WO2011161256A1 (en) | 2010-06-25 | 2011-12-29 | Facultes Universitaires Notre Dame De La Paix | Beta carboline derivatives useful in the treatment of proliferative disorders |
US8785648B1 (en) | 2010-08-10 | 2014-07-22 | The Regents Of The University Of California | PKC-epsilon inhibitors |
EP3187197B1 (en) | 2010-08-18 | 2020-01-01 | Emory University | Compounds and compositions for ossification and methods related thereto |
WO2012022780A1 (en) | 2010-08-19 | 2012-02-23 | Université Libre de Bruxelles | 18-beta-glycyrrhetinic acid derivatives with anti-tumor activity |
WO2012032389A2 (en) | 2010-09-10 | 2012-03-15 | Lupin Limited | Process for preparation of substantially pure fosamprenavir calcium and its intermediates |
EP2632895B1 (en) | 2010-10-28 | 2018-10-03 | Merck Canada Inc. | Hiv protease inhibitors |
EP2886120B1 (en) | 2010-10-29 | 2019-06-19 | Emory University | Quinazoline derivatives, compositions and uses related thereto |
GB201019043D0 (en) | 2010-11-10 | 2010-12-22 | Protea Biopharma N V | Use of 2',5'-oligoadenylate derivative compounds |
WO2012075362A2 (en) | 2010-12-03 | 2012-06-07 | Emory University | Chemokine cxcr4 receptor modulators and used related thereto |
CN102584748B (zh) * | 2011-01-13 | 2015-02-11 | 浙江九洲药业股份有限公司 | 夫沙那韦中间体的制备方法 |
US8691777B2 (en) | 2011-01-27 | 2014-04-08 | Emory University | Combination therapy |
CA2827392A1 (en) | 2011-02-24 | 2012-08-30 | Emory University | Noggin blocking compositions for ossification and methods related thereto |
US11179500B2 (en) | 2011-02-24 | 2021-11-23 | Emory University | JAB1 inhibitory compositions for ossification and methods related thereto |
US9365523B2 (en) | 2011-03-31 | 2016-06-14 | Emory University | Imidazolyl amide compounds and uses related thereto |
WO2012145234A2 (en) | 2011-04-21 | 2012-10-26 | Emory University | Cyclopropyl derivatives and methods of use |
GB201107223D0 (en) | 2011-04-29 | 2011-06-15 | Amakem Nv | Novel rock inhibitors |
JP2014518859A (ja) | 2011-05-09 | 2014-08-07 | ユニバーシタット アントウェルペン | ウロキナーゼプラスミノーゲン活性化因子に対する活性依存型プローブ |
GB201108225D0 (en) | 2011-05-17 | 2011-06-29 | Amakem Nv | Novel KBC inhibitors |
US9518044B2 (en) | 2011-06-20 | 2016-12-13 | Emory University | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto |
WO2013011485A1 (en) | 2011-07-20 | 2013-01-24 | Ranbaxy Laboratories Limited | Process for the preparation of sulfonamides useful as retroviral protease inhibitors |
GB201113689D0 (en) | 2011-08-09 | 2011-09-21 | Amakem Nv | Novel PDE4 inhibitors |
US9040567B2 (en) | 2011-08-19 | 2015-05-26 | Emory University | BAX agonist, compositions, and methods related thereto |
GB201114854D0 (en) | 2011-08-29 | 2011-10-12 | Amakem Nv | Novel rock inhibitors |
CA2846752A1 (en) | 2011-08-31 | 2013-03-07 | Amakem Nv | Biphenylcarboxamides as rock kinase inhibitors |
CA2850350A1 (en) | 2011-09-30 | 2013-04-04 | Ipsen Pharma S.A.S. | Macrocyclic lrrk2 kinase inhibitors |
MX347765B (es) | 2011-09-30 | 2017-05-12 | Oncodesign Sa | Inhibidores macrociclicos de la quinasa flt3. |
EP2771332B1 (en) | 2011-10-26 | 2016-06-29 | Merck Canada Inc. | Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS |
GB201119358D0 (en) | 2011-11-10 | 2011-12-21 | Lewi Paulus J | Disubstituted triazine dimers for treatment and/or prevention of infectious diseases |
PL2810198T3 (pl) | 2012-01-30 | 2024-01-22 | Universiteit Gent | Związki przeciwinwazyjne |
GB201204756D0 (en) | 2012-03-19 | 2012-05-02 | Lewi Paulus J | Triazines with suitable spacers for treatment and/or prevention of HIV infections |
WO2013181135A1 (en) | 2012-05-31 | 2013-12-05 | Emory University | Quinazoline derivatives, compositions, and uses related thereto |
US9593125B2 (en) | 2012-07-27 | 2017-03-14 | Emory University | Heterocyclic flavone derivatives, compositions, and methods related thereto |
KR20150053971A (ko) | 2012-09-11 | 2015-05-19 | 머크 샤프 앤드 돔 코포레이션 | Hiv 프로테아제 억제제 |
WO2014059034A2 (en) | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
KR102186030B1 (ko) | 2012-10-29 | 2020-12-03 | 시플라 리미티드 | 항 바이러스성 포스포네이트 유사체 및 이의 제조를 위한 방법 |
AU2013337742B2 (en) | 2012-11-05 | 2017-11-23 | Emory University | 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto |
WO2014072419A1 (en) | 2012-11-08 | 2014-05-15 | Universiteit Antwerpen | Novel anti-hiv compounds |
SI2951172T1 (sl) | 2013-01-29 | 2017-08-31 | Redx Pharma Plc | Piridin derivati kot inhibitorji mehkih kamnov |
BR112015022650A8 (pt) | 2013-03-15 | 2018-01-23 | Oncodesign Sa | inibidores de quinase induzível por sal macrocíclico. |
WO2015013835A1 (en) | 2013-07-31 | 2015-02-05 | Merck Sharp & Dohme Corp. | Piperazine derivatives as hiv protease inhibitors |
JP6762873B2 (ja) | 2013-09-11 | 2020-09-30 | エモリー・ユニバーシテイ | ヌクレオチドおよびヌクレオシド組成物ならびにこれらに関連する使用 |
US10188738B2 (en) | 2013-10-16 | 2019-01-29 | Université Libre de Bruxelles | Formulations useful in the treatment of proliferative diseases affecting the respiratory tract |
US10159755B2 (en) | 2013-11-12 | 2018-12-25 | Vrije Universiteit Brussel | RNA transcription vector and uses thereof |
WO2015095276A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Hiv protease inhibitors |
US9994587B2 (en) | 2014-03-06 | 2018-06-12 | Merck Sharp & Dohme Corp. | HIV protease inhibitors |
WO2015150337A1 (en) | 2014-04-01 | 2015-10-08 | Amakem Nv | Lim kinase inhibitors |
WO2015150472A2 (en) | 2014-04-01 | 2015-10-08 | Université Libre de Bruxelles | New strategies for treating melanoma |
EP3140275B1 (en) | 2014-05-05 | 2020-07-08 | Emory University | Combination of a bh4 antagonist and a mtor inhibitor for lung cancer therapy |
EP3143005B1 (en) | 2014-05-16 | 2021-07-07 | Emory University | Chemokine cxcr4 and ccr5 receptor modulators and used related thereto |
WO2016003450A1 (en) | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Pkc-epsilon inhibitors |
WO2016005340A1 (en) | 2014-07-08 | 2016-01-14 | Universiteit Gent | Hamamelitannin analogues and uses thereof |
MY186523A (en) | 2014-09-17 | 2021-07-24 | Oncodesign Sa | Macrocyclic rip2 kinase inhibitors |
EP3194405B1 (en) | 2014-09-17 | 2018-12-26 | Oncodesign S.A. | Macrocyclic lrrk2 kinase inhibitors |
US9738664B2 (en) | 2014-10-29 | 2017-08-22 | Wisconsin Alumni Research Foundation | Boronic acid inhibitors of HIV protease |
WO2016083490A1 (en) | 2014-11-27 | 2016-06-02 | Remynd Nv | Compounds for the treatment of amyloid-associated diseases |
SG11201704785RA (en) | 2014-12-15 | 2017-07-28 | Univ Emory | Phosphoramidates for the treatment of hepatitis b virus |
BR112017013858A2 (pt) | 2014-12-26 | 2018-02-27 | Univ Emory | n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos |
WO2016146651A1 (en) | 2015-03-16 | 2016-09-22 | Oncodesign Sa | Macrocyclic activin-like receptor kinase inhibitors |
PT3288637T (pt) | 2015-04-28 | 2022-10-11 | Newsouth Innovations Pty Ltd | Visar nad+ para tratar comprometimento cognitivo, neuropatias e inatividade induzidos por quimioterapia e radioterapia |
WO2016196297A1 (en) | 2015-05-29 | 2016-12-08 | Emory University | 2-amino-n'-benzylideneacetohydrazides and derivatives for the management of cftr protein mediated diseases |
EP3423113B1 (en) | 2016-02-29 | 2020-09-02 | Oncodesign S.A. | Radiolabeled macrocyclic egfr inhibitor |
WO2017157882A1 (en) | 2016-03-14 | 2017-09-21 | Université Catholique de Louvain | Serine biosynthetic pathway inhibitors |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
WO2017198753A1 (en) | 2016-05-19 | 2017-11-23 | Universiteit Antwerpen | Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases |
BE1023757B1 (nl) | 2016-06-30 | 2017-07-12 | Yun NV | Bewaring van micro-organismen |
WO2018065387A1 (en) | 2016-10-04 | 2018-04-12 | Universiteit Gent | Novel hamamelitannin analogues and uses thereof |
WO2018071911A1 (en) | 2016-10-14 | 2018-04-19 | Emory University | Nanoparticles having molecules that bind or block pd-l1 and uses in treating cancer |
US11331297B2 (en) | 2016-10-26 | 2022-05-17 | Emory University | Polyoxometalate complexes and uses in managing cancer |
WO2018096088A1 (en) | 2016-11-24 | 2018-05-31 | Universiteit Antwerpen | Halogenated benzotropolones as atg4b inhibitors |
CA3046927A1 (en) | 2016-12-13 | 2018-06-21 | Emory University | Polypeptides for managing viral infections |
EP3573608A1 (en) | 2017-01-30 | 2019-12-04 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
IL269379B (en) | 2017-02-21 | 2022-06-01 | Univ Emory | cxcr4 receptor modulators and related uses |
EP3621963B1 (en) | 2017-05-11 | 2024-01-24 | Remynd N.V. | Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders |
EP3960740B1 (en) | 2017-08-01 | 2023-11-15 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections |
BR112020009361A2 (pt) | 2017-11-17 | 2020-10-13 | Cellix Bio Private Limited | composto de fórmula i, composição farmacêutica para tratar um distúrbio ocular ou complicações do mesmo, método de síntese de composto, método de tratamento de um distúrbio ocular ou complicações do mesmo em um indivíduo que precisa do mesmo e uso de um composto |
MX2020005392A (es) | 2017-12-07 | 2020-12-07 | Univ Emory | N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos. |
US20210145838A1 (en) | 2018-04-05 | 2021-05-20 | Universiteit Hasselt | Selective pde4d inhibitors against demyelinating diseases |
BR112020026456A2 (pt) | 2018-06-29 | 2021-03-23 | Rejuvenate Biomed | Combinação farmacêutica para o uso em doenças relacionadas com a idade e/ou degenerativas |
EP4344743A2 (en) | 2018-08-07 | 2024-04-03 | Emory University | Heterocyclic flavone derivatives, compositions, and methods related thereto |
EP3843845A4 (en) | 2018-08-29 | 2022-05-11 | University Of Massachusetts | INHIBITION OF PROTEIN KINASE FOR THE TREATMENT OF FRIEDREICH'S ATAXIA |
EP3969450B1 (en) | 2019-05-14 | 2023-10-25 | Suzhou Four Health Pharmaceuticals Co., Ltd | Quinazoline-2,4-dione derivatives as parp inhibitors |
US20230130598A1 (en) | 2020-02-24 | 2023-04-27 | Katholieke Universiteit Leuven | Pyrrolopyridine and imidazopyridine antiviral compounds |
GB202003240D0 (en) | 2020-03-05 | 2020-04-22 | Ecosynth Nv | Antiviral treatment |
WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
WO2022157381A1 (en) | 2021-01-25 | 2022-07-28 | Universiteit Hasselt | Phloretin for use in the treatment of neurodegenerative and demyelinating diseases |
IL310330A (en) | 2021-07-30 | 2024-03-01 | Confo Therapeutics N V | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders associated with AT2R and/or AT2R-mediated signaling |
WO2023021132A1 (en) | 2021-08-18 | 2023-02-23 | Katholieke Universiteit Leuven | 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues |
WO2023046900A1 (en) | 2021-09-23 | 2023-03-30 | Katholieke Universiteit Leuven | Ribonucleoside analogues against -sars-cov-2 |
WO2023105283A1 (en) | 2021-12-08 | 2023-06-15 | Fundacio Privada Institut De Recerca De La Sida - Caixa | Nucleoside reverse transcriptase inhibitors for use in down syndrome and alzheimer`s disease therapy |
WO2023111683A1 (en) | 2021-12-16 | 2023-06-22 | Ascletis Bioscience Co., Ltd. | N4-hydroxycytidine derivatives and use thereof as antiviral agent |
US11541071B1 (en) | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
WO2023139402A1 (en) | 2022-01-18 | 2023-07-27 | Ascletis Bioscience Co., Ltd. | Inhibitors of cysteine proteases and methods of use thereof |
US11760722B2 (en) | 2022-01-18 | 2023-09-19 | Ascletis Bioscience Co., Ltd. | Inhibitors of cysteine proteases and methods of use thereof |
WO2023180567A1 (en) | 2022-03-24 | 2023-09-28 | Fundacion Privada Institut De Recerca De La Sida-Caixa | Cyclodextrins for use in coronavirus infection therapy |
WO2023241799A1 (en) | 2022-06-15 | 2023-12-21 | Université Libre de Bruxelles | Flavanols for use in the treatment of retroviral infections |
WO2024009120A1 (en) | 2022-07-08 | 2024-01-11 | Ascletis Bioscience Co., Ltd. | Triazine derivatives and methods of use thereof |
CN116514783A (zh) | 2022-11-21 | 2023-08-01 | 歌礼生物科技(杭州)有限公司 | 三嗪衍生物 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3743722A (en) | 1971-07-14 | 1973-07-03 | Abbott Lab | Anti-coagulant isolation |
FR2459235A1 (fr) * | 1979-06-14 | 1981-01-09 | Sanofi Sa | Nouveaux derives de sulfonyl-aniline, leur procede de preparation et leur application therapeutique |
JPS5946252A (ja) * | 1982-09-09 | 1984-03-15 | Dainippon Ink & Chem Inc | 含フツ素アミノカルボキシレ−トおよびその製法 |
JPS5948449A (ja) * | 1982-09-13 | 1984-03-19 | Dainippon Ink & Chem Inc | 直鎖状含フツ素アニオン化合物およびその製造方法 |
JPS6171830A (ja) * | 1984-09-17 | 1986-04-12 | Dainippon Ink & Chem Inc | 界面活性剤組成物 |
US4616088A (en) * | 1984-10-29 | 1986-10-07 | E. R. Squibb & Sons, Inc. | Amino acid ester and amide renin inhibitor |
US4629724A (en) * | 1984-12-03 | 1986-12-16 | E. R. Squibb & Sons, Inc. | Amino acid ester and amide renin inhibitors |
DE3635907A1 (de) * | 1986-10-22 | 1988-04-28 | Merck Patent Gmbh | Hydroxy-aminosaeurederivate |
NL8800100A (nl) * | 1987-01-21 | 1988-08-16 | Sandoz Ag | Nieuwe peptidederivaten en werkwijzen voor het bereiden en toepassen van deze derivaten. |
CA1340588C (en) * | 1988-06-13 | 1999-06-08 | Balraj Krishan Handa | Amino acid derivatives |
IL91780A (en) | 1988-10-04 | 1995-08-31 | Abbott Lab | History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them |
WO1990007330A1 (en) | 1989-01-06 | 1990-07-12 | The Regents Of The University Of California | Selection method for specific useful pharmaceutical compounds |
US5354866A (en) * | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5151438A (en) * | 1989-05-23 | 1992-09-29 | Abbott Laboratories | Retroviral protease inhibiting compounds |
IE902295A1 (en) | 1989-07-07 | 1991-01-16 | Abbott Lab | Amino acid analog cck antagonists |
GB8927913D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
JPH07502970A (ja) * | 1990-06-01 | 1995-03-30 | ザ・デュポン・メルク・ファーマシュウティカル・カンパニー | 1,4―ジアミノ―2,3―ジヒドロキシブタン類 |
TW225540B (da) * | 1990-06-28 | 1994-06-21 | Shionogi & Co | |
EP0815856B1 (en) * | 1990-11-19 | 2005-06-01 | Monsanto Company | Retroviral protease inhibitors |
ES2059289T3 (es) * | 1990-11-19 | 1997-10-16 | Monsanto Co | Inhibidores de la proteasa retroviral. |
AU9125191A (en) | 1990-11-19 | 1992-06-11 | Monsanto Company | Retroviral protease inhibitors |
DE69124110T2 (de) * | 1990-11-19 | 1997-06-05 | Monsanto Co | Retrovirale protease inhibitoren |
IE913840A1 (en) * | 1990-11-20 | 1992-05-20 | Abbott Lab | Retroviral protease inhibiting compounds |
DK0541168T3 (da) | 1991-11-08 | 1998-05-11 | Merck & Co Inc | HIV-proteaseinhibitorer, som er egnede til behandling af AIDS |
KR100290516B1 (ko) * | 1992-05-20 | 2001-09-17 | 죤 에이치. 뷰센 | 레트로바이러스프로테아제억제인자의합성에유용한중간생성물의제조방법 |
CA2136312A1 (en) * | 1992-05-21 | 1993-11-25 | Michael Clare | Retroviral protease inhibitors |
EP0656888B1 (en) * | 1992-08-25 | 1998-01-07 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US5843946A (en) * | 1992-08-25 | 1998-12-01 | G.D. Searle & Co. | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
DE69311810T2 (de) * | 1992-08-25 | 1997-11-27 | Searle & Co | N-(alkanoylamino-2-hydroxypropyl)-sulfonamide verwendbar als retrovirale proteaseninhibitoren |
US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
EP0885881B1 (en) * | 1992-10-30 | 2003-03-12 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors |
CA2142997A1 (en) * | 1992-10-30 | 1994-05-11 | Michael L. Vazquez | Hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors |
AU6135294A (en) * | 1993-02-12 | 1994-08-29 | Merck & Co., Inc. | Piperazine derivatives as hiv protease inhibitors |
JP3419539B2 (ja) * | 1993-02-17 | 2003-06-23 | 中外製薬株式会社 | インドリン−2−オン誘導体 |
-
1993
- 1993-08-31 IS IS4068A patent/IS2334B/is unknown
- 1993-09-01 LT LTIP917A patent/LT3302B/lt not_active IP Right Cessation
- 1993-09-01 TW TW082107130A patent/TW254927B/zh not_active IP Right Cessation
- 1993-09-06 IL IL10692793A patent/IL106927A/en not_active IP Right Cessation
- 1993-09-07 GE GEAP19932481A patent/GEP20012579B/en unknown
- 1993-09-07 HU HU9500685A patent/HU228198B1/hu unknown
- 1993-09-07 CA CA002143208A patent/CA2143208C/en not_active Expired - Lifetime
- 1993-09-07 JP JP6507525A patent/JP3012002B2/ja not_active Expired - Lifetime
- 1993-09-07 ES ES98113921T patent/ES2200243T3/es not_active Expired - Lifetime
- 1993-09-07 ES ES93921428T patent/ES2131589T3/es not_active Expired - Lifetime
- 1993-09-07 DE DE69333012T patent/DE69333012T2/de not_active Expired - Lifetime
- 1993-09-07 SK SK293-95A patent/SK281360B6/sk not_active IP Right Cessation
- 1993-09-07 DE DE2001199024 patent/DE10199024I2/de active Active
- 1993-09-07 DE DE69324369T patent/DE69324369T2/de not_active Expired - Lifetime
- 1993-09-07 DK DK98113921T patent/DK0885887T3/da active
- 1993-09-07 AU AU48520/93A patent/AU691160B2/en not_active Expired
- 1993-09-07 EP EP98113921A patent/EP0885887B1/en not_active Expired - Lifetime
- 1993-09-07 UA UA95048318A patent/UA44694C2/uk unknown
- 1993-09-07 US US08/142,327 patent/US5585397A/en not_active Expired - Lifetime
- 1993-09-07 RO RO95-00479A patent/RO118747B1/ro unknown
- 1993-09-07 WO PCT/US1993/008458 patent/WO1994005639A1/en not_active Application Discontinuation
- 1993-09-07 DK DK93921428T patent/DK0659181T3/da active
- 1993-09-07 PT PT98113921T patent/PT885887E/pt unknown
- 1993-09-07 PH PH46835A patent/PH31251A/en unknown
- 1993-09-07 AT AT93921428T patent/ATE178598T1/de active
- 1993-09-07 SG SG1996003219A patent/SG43862A1/en unknown
- 1993-09-07 EP EP93921428A patent/EP0659181B1/en not_active Expired - Lifetime
- 1993-09-07 NZ NZ256238A patent/NZ256238A/en not_active IP Right Cessation
- 1993-09-07 KR KR1019950700920A patent/KR100262056B1/ko not_active IP Right Cessation
- 1993-09-07 AT AT98113921T patent/ATE241602T1/de active
- 1993-09-07 NZ NZ314376A patent/NZ314376A/xx not_active IP Right Cessation
- 1993-09-07 RU RU95109928A patent/RU2135496C1/ru active
- 1993-09-07 CZ CZ1995587A patent/CZ289475B6/cs not_active IP Right Cessation
- 1993-09-07 CO CO93406779A patent/CO4870779A1/es unknown
- 1993-09-07 PL PL93307858A patent/PL185635B1/pl unknown
- 1993-09-08 AP APAP/P/1993/000572A patent/AP390A/en active
- 1993-09-08 CN CN93117370A patent/CN1061339C/zh not_active Expired - Lifetime
- 1993-09-08 MY MYPI93001823A patent/MY142901A/en unknown
-
1995
- 1995-03-07 NO NO950876A patent/NO303444B1/no not_active IP Right Cessation
- 1995-03-07 FI FI951059A patent/FI120685B/fi not_active IP Right Cessation
- 1995-04-03 BG BG99540A patent/BG62488B1/bg unknown
- 1995-06-07 US US08/477,937 patent/US5856353A/en not_active Expired - Lifetime
- 1995-06-07 US US08/484,326 patent/US6372778B1/en not_active Expired - Lifetime
-
1997
- 1997-05-12 BR BR1100824-5A patent/BR1100824A/pt active IP Right Grant
-
1998
- 1998-12-17 HK HK00100689A patent/HK1023561A1/xx not_active IP Right Cessation
- 1998-12-17 HK HK98113971A patent/HK1012631A1/xx not_active IP Right Cessation
-
1999
- 1999-07-07 GR GR990401802T patent/GR3030719T3/el unknown
-
2000
- 2000-01-01 NL NL300039C patent/NL300039I2/nl unknown
- 2000-03-31 CY CY0000008A patent/CY2164B1/xx unknown
-
2001
- 2001-03-07 LU LU90736C patent/LU90736I2/fr unknown
- 2001-07-03 NO NO2001012C patent/NO2001012I1/no unknown
-
2002
- 2002-03-08 US US10/094,790 patent/US20030069222A1/en not_active Abandoned
-
2003
- 2003-11-17 MX MXPA03010538A patent/MXPA03010538A/es active IP Right Grant
-
2006
- 2006-04-19 US US11/408,287 patent/US7608632B2/en not_active Expired - Fee Related
-
2007
- 2007-12-12 US US12/001,993 patent/US20080293727A1/en not_active Abandoned
-
2009
- 2009-09-11 US US12/558,051 patent/US20100210603A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0659181T3 (da) | Sulfonamidinhibitorer af HIV-aspartylprotease | |
DK0846110T3 (da) | THF-holdige sulfonamidinhibitorer af aspartylprotease | |
NO974744D0 (no) | Oksygenert-heterocykelinneholdende sulfonamidhemmere av aspartylprotease | |
DE69431193T2 (de) | Hiv - protease inhibitoren | |
DK1086076T3 (da) | Sulfonamidinhibitorer af aspartylprotease | |
DK633189D0 (da) | Anvendelse af peptidisostere som retrovirale proteasehaemmere | |
FI935644A (fi) | Retrovirusten proteaasi-inhibiittoreita | |
FI962073A0 (fi) | HIV-proteaasin estäjän prodrug-muotoja | |
FI932847A (fi) | Hiv-proteasinhibitorer som aer anvaendbara foer behandling av aids | |
ZA938470B (en) | Sulfonamide inhibitors of aspartyl protease | |
NO920023L (no) | Hiv-proteaseinhibitorer |